Timo Hänninen appointed CEO of Injeq Oy
Timo Hänninen, Ph.D., MBA, has been appointed CEO of Injeq Oy. Hänninen will take up his position at 14.2.2022. Hänninen has previously served as the CEO of RUAG Space Finland Oy AB.
Timo Hänninen is a professional with a long experience in managing technology organizations. He has extensive experience in international business development and strategy. During his career, Hänninen has worked in the fields of medical technology, cyber security and space technology, as well as in management positions at Nokia Corporation for almost 20 years.
Hänninen's educational background is also diverse. He did his Master’s thesis on medical technology, his MBA work dealt with Nokia’s ethical management, and his dissertation focused on the Investor Reactions to Corporate Merger and Acquisition Announcements.
Hänninen is interested in Injeq’s high technology and the global market. It is also important to him that Injeq is a Finnish company whose product can improve people's lives. “Injeq is a truly international company that creates something new. I see the purpose of the work as an important motivating factor”, says Hänninen.
Hänninen describes himself as a pragmatic value leader who leads based on facts. “I am an open, listener and respect everyone in the organization. I want to challenge the organization, and as a team player, I believe in innovation through individuals and working together”, Hänninen estimates.
“I am very pleased that a management professional CEO with extensive experience and a solid business vision has been appointed to Injeq. We are an international growth company in medical high-technology that needs expertise like Hänninen”, says Injeq's Chairman of the Board and Acting CEO Tommi Rasila.
Hänninen has solid experience in bringing new technology into markets. While at Nokia, he was selling cellular networks to areas where even the wired telephone networks were not working perfectly.
Tommi Rasila, Chairman of the Board, Acting CEO
tel. +358 40 750 8158
Timo Hänninen, CEO since 14.2.2022
tel. +358 50 518 1830
Injeq in brief
Injeq Oy is a Finnish growth company in innovative medical technology, whose mission is to produce technically intelligent solutions for medically demanding patient injections. Developed at the request of physicians, the IQ-Tip® smart needle facilitates physicians' work to improve patient safety and treatment effectiveness.
The IQ-Tip® smart needle is a modern way to perform demanding patient injections safely. The first stage is lumbar puncture, a clinical procedure in which the spinal fluid is sampled or a drug is administered into the spinal cavity. The clinical performance and safety of the product at lumbar punctures have been evaluated in three clinical trials in Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, one of the main uses being for the treatment of leukemia children.
Founded in 2010, Injeq operates in Tampere and currently employs 16 people. Injeq is supported by an experienced team of medical experts and extensive scientific research. IQ-Tip® is a registered trademark of Injeq.